ANI Pharmaceuticals, Inc. (ANIP)
USD 68.72
(0.88%)
USD 68.72
(0.88%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 486.81 Million USD | 53.87% |
| 2022 | 316.38 Million USD | 46.38% |
| 2021 | 216.13 Million USD | 3.67% |
| 2020 | 208.47 Million USD | 0.93% |
| 2019 | 206.54 Million USD | 2.47% |
| 2018 | 201.57 Million USD | 13.99% |
| 2017 | 176.84 Million USD | 37.49% |
| 2016 | 128.62 Million USD | 68.53% |
| 2015 | 76.32 Million USD | 36.36% |
| 2014 | 55.97 Million USD | 86.06% |
| 2013 | 30.08 Million USD | 1207.49% |
| 2012 | 2.3 Million USD | 428.71% |
| 2011 | 435.16 Thousand USD | -82.41% |
| 2010 | 2.47 Million USD | 96.67% |
| 2009 | 1.25 Million USD | -66.73% |
| 2008 | 3.78 Million USD | 666.82% |
| 2007 | 493.05 Thousand USD | -96.59% |
| 2006 | 14.43 Million USD | 5488.76% |
| 2005 | 258.35 Thousand USD | 231.7% |
| 2004 | 77.88 Thousand USD | 18.92% |
| 2003 | 65.49 Thousand USD | -97.69% |
| 2002 | 2.83 Million USD | 62.18% |
| 2001 | 1.74 Million USD | 87369200.0% |
| 2000 | 2.00 USD | 100.0% |
| 1999 | 1.00 USD | -100.0% |
| 1998 | 123.06 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 137.43 Million USD | 4.39% |
| 2024 Q2 | 138.04 Million USD | 0.44% |
| 2023 FY | 486.81 Million USD | 53.87% |
| 2023 Q1 | 106.78 Million USD | 13.32% |
| 2023 Q2 | 116.54 Million USD | 9.14% |
| 2023 Q3 | 131.82 Million USD | 13.11% |
| 2023 Q4 | 131.65 Million USD | -0.13% |
| 2022 Q4 | 94.23 Million USD | 12.42% |
| 2022 FY | 316.38 Million USD | 46.38% |
| 2022 Q3 | 83.82 Million USD | 13.49% |
| 2022 Q1 | 64.47 Million USD | 5.82% |
| 2022 Q2 | 73.85 Million USD | 14.54% |
| 2021 Q1 | 54.52 Million USD | -4.77% |
| 2021 Q2 | 48.62 Million USD | -10.81% |
| 2021 FY | 216.13 Million USD | 3.67% |
| 2021 Q3 | 52.06 Million USD | 7.07% |
| 2021 Q4 | 60.92 Million USD | 17.03% |
| 2020 Q2 | 48.47 Million USD | -2.62% |
| 2020 Q1 | 49.77 Million USD | 3.77% |
| 2020 Q3 | 52.97 Million USD | 9.3% |
| 2020 FY | 208.47 Million USD | 0.93% |
| 2020 Q4 | 57.25 Million USD | 8.07% |
| 2019 FY | 206.54 Million USD | 2.47% |
| 2019 Q4 | 47.96 Million USD | -6.57% |
| 2019 Q2 | 54.35 Million USD | 2.78% |
| 2019 Q3 | 51.33 Million USD | -5.56% |
| 2019 Q1 | 52.88 Million USD | -7.41% |
| 2018 Q1 | 46.48 Million USD | -1.7% |
| 2018 Q3 | 50.7 Million USD | 7.27% |
| 2018 Q2 | 47.26 Million USD | 1.69% |
| 2018 FY | 201.57 Million USD | 13.99% |
| 2018 Q4 | 57.12 Million USD | 12.66% |
| 2017 Q4 | 47.28 Million USD | -1.82% |
| 2017 FY | 176.84 Million USD | 37.49% |
| 2017 Q3 | 48.16 Million USD | 7.6% |
| 2017 Q2 | 44.76 Million USD | 22.21% |
| 2017 Q1 | 36.62 Million USD | -4.13% |
| 2016 Q2 | 31.33 Million USD | 52.45% |
| 2016 Q1 | 20.55 Million USD | 13.97% |
| 2016 FY | 128.62 Million USD | 68.53% |
| 2016 Q4 | 38.2 Million USD | -0.83% |
| 2016 Q3 | 38.52 Million USD | 22.94% |
| 2015 Q1 | 18.79 Million USD | -10.64% |
| 2015 Q2 | 19.51 Million USD | 3.81% |
| 2015 FY | 76.32 Million USD | 36.36% |
| 2015 Q3 | 19.97 Million USD | 2.34% |
| 2015 Q4 | 18.03 Million USD | -9.7% |
| 2014 Q3 | 17.38 Million USD | 161.58% |
| 2014 Q2 | 6.64 Million USD | -39.01% |
| 2014 Q4 | 21.03 Million USD | 20.99% |
| 2014 Q1 | 10.89 Million USD | 3.48% |
| 2014 FY | 55.97 Million USD | 86.06% |
| 2013 Q1 | 145.04 Thousand USD | -92.63% |
| 2013 FY | 30.08 Million USD | 1207.49% |
| 2013 Q4 | 10.53 Million USD | 34.4% |
| 2013 Q3 | 7.83 Million USD | 27.39% |
| 2013 Q2 | 6.15 Million USD | 4141.27% |
| 2012 Q4 | 1.96 Million USD | 1682.5% |
| 2012 Q2 | 108.78 Thousand USD | -4.58% |
| 2012 Q1 | 114 Thousand USD | -0.33% |
| 2012 FY | 2.3 Million USD | 428.71% |
| 2012 Q3 | 110.38 Thousand USD | 1.47% |
| 2011 Q3 | 182.78 Thousand USD | 125.65% |
| 2011 Q1 | 57 Thousand USD | -60.15% |
| 2011 FY | 435.16 Thousand USD | -82.41% |
| 2011 Q4 | 114.37 Thousand USD | -37.43% |
| 2011 Q2 | 81 Thousand USD | 42.11% |
| 2010 Q2 | - USD | -100.0% |
| 2010 FY | 2.47 Million USD | 96.67% |
| 2010 Q1 | 2.27 Million USD | 114.28% |
| 2010 Q4 | 143.03 Thousand USD | 178.65% |
| 2010 Q3 | 51.33 Thousand USD | 0.0% |
| 2009 Q1 | 68.42 Thousand USD | -98.1% |
| 2009 FY | 1.25 Million USD | -66.73% |
| 2009 Q3 | 10.49 Thousand USD | -90.89% |
| 2009 Q2 | 115.16 Thousand USD | 68.3% |
| 2009 Q4 | 1.06 Million USD | 10040.78% |
| 2008 Q3 | 82.21 Thousand USD | 217.8% |
| 2008 Q2 | 25.86 Thousand USD | -43.27% |
| 2008 Q1 | 45.59 Thousand USD | -86.15% |
| 2008 FY | 3.78 Million USD | 666.82% |
| 2008 Q4 | 3.6 Million USD | 4290.78% |
| 2007 Q2 | 69.44 Thousand USD | 37.22% |
| 2007 Q3 | 43.79 Thousand USD | -36.94% |
| 2007 Q1 | 50.6 Thousand USD | -99.64% |
| 2007 Q4 | 329.2 Thousand USD | 651.73% |
| 2007 FY | 493.05 Thousand USD | -96.59% |
| 2006 Q1 | 84.67 Thousand USD | -12.68% |
| 2006 FY | 14.43 Million USD | 5488.76% |
| 2006 Q3 | 140.32 Thousand USD | -19.93% |
| 2006 Q4 | 14.03 Million USD | 9904.25% |
| 2006 Q2 | 175.25 Thousand USD | 106.96% |
| 2005 Q2 | 45.59 Thousand USD | 59.0% |
| 2005 Q4 | 96.97 Thousand USD | 11.33% |
| 2005 Q1 | 28.67 Thousand USD | -47.7% |
| 2005 Q3 | 87.1 Thousand USD | 91.04% |
| 2005 FY | 258.35 Thousand USD | 231.7% |
| 2004 Q2 | 4976.00 USD | -31.98% |
| 2004 Q3 | 10.76 Thousand USD | 116.28% |
| 2004 Q4 | 54.83 Thousand USD | 409.5% |
| 2004 FY | 77.88 Thousand USD | 18.92% |
| 2004 Q1 | 7316.00 USD | 113.13% |
| 2003 Q1 | 84.31 Thousand USD | -95.42% |
| 2003 FY | 65.49 Thousand USD | -97.69% |
| 2003 Q4 | -55.7 Thousand USD | -319.33% |
| 2003 Q3 | 25.39 Thousand USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2002 FY | 2.83 Million USD | 62.18% |
| 2002 Q4 | 1.84 Million USD | 91.3% |
| 2002 Q3 | 962.55 Thousand USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 100.0% |
| 2001 Q1 | 1.00 USD | 0.0% |
| 2001 Q4 | -1.79 Million USD | -202.91% |
| 2001 FY | 1.74 Million USD | 87369200.0% |
| 2001 Q3 | 1.74 Million USD | 3336.83% |
| 2001 Q2 | 50.84 Thousand USD | 5084200.0% |
| 2000 Q4 | 1.00 USD | 0.0% |
| 2000 Q1 | 1.00 USD | 0.0% |
| 2000 FY | 2.00 USD | 100.0% |
| 2000 Q3 | 1.00 USD | 0.0% |
| 2000 Q2 | 1.00 USD | 0.0% |
| 1999 FY | 1.00 USD | -100.0% |
| 1999 Q2 | - USD | 0.0% |
| 1998 FY | 123.06 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 14.107% |
| Embecta Corp. | 1.12 Billion USD | 56.565% |
| Dynavax Technologies Corporation | 232.28 Million USD | -109.578% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -318.464% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 27.877% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -862.41% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1920.588% |
| SCYNEXIS, Inc. | 140.14 Million USD | -247.376% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -25143.285% |
| Cosmos Health Inc. | 53.37 Million USD | -812.035% |
| Journey Medical Corporation | 79.18 Million USD | -514.814% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -1920.588% |
| Safety Shot Inc | 202.67 Thousand USD | -240101.312% |
| Alpha Teknova, Inc. | 36.68 Million USD | -1227.053% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -4.834% |
| Bright Green Corporation | 401.49 Thousand USD | -121152.033% |
| Procaps Group, S.A. | 409.92 Million USD | -18.759% |
| Theratechnologies Inc. | 81.76 Million USD | -495.392% |
| Harrow Health, Inc. | 130.19 Million USD | -273.919% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -3722.662% |
| Biofrontera Inc. | 34.07 Million USD | -1328.828% |
| DURECT Corporation | 8.54 Million USD | -5595.087% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 19.868% |
| Cronos Group Inc. | 88.84 Million USD | -447.964% |
| OptiNose, Inc. | 70.98 Million USD | -585.782% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -9.957% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -7374.329% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -12.392% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -3874.479% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1130.809% |
| Radius Health, Inc. | 2.88 Billion USD | 83.11% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -1406.763% |
| ProPhase Labs, Inc. | 44.38 Million USD | -996.828% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 52.164% |
| Procaps Group S.A. | 409.92 Million USD | -18.759% |
| Alvotech | 91.43 Million USD | -432.423% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -37289.862% |
| Viatris Inc. | 15.42 Billion USD | 96.844% |
| Rockwell Medical, Inc. | 83.61 Million USD | -482.232% |
| Aytu BioPharma, Inc. | 81 Million USD | -500.993% |
| SIGA Technologies, Inc. | 139.91 Million USD | -247.931% |
| Tilray Brands, Inc. | 788.94 Million USD | 38.295% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -279.551% |
| Shineco, Inc. | 9.8 Million USD | -4866.57% |
| PetIQ, Inc. | 1.1 Billion USD | 55.823% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -4056700.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 74.203% |
| Alimera Sciences, Inc. | 80.75 Million USD | -502.838% |
| Silver Spike Investment Corp. | 11.72 Million USD | -4052.964% |
| Assertio Holdings, Inc. | 152.06 Million USD | -220.128% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -8261.105% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -2695.062% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -45126.1% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -1640.929% |
| Hempacco Co., Inc. | 4.04 Million USD | -11933.111% |
| Talphera, Inc. | 651 Thousand USD | -74679.724% |
| Alvotech | 91.43 Million USD | -432.423% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -53.759% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 62.449% |
| Currenc Group, Inc. | 53.25 Million USD | -814.116% |
| Kamada Ltd. | 144.75 Million USD | -236.295% |
| Indivior PLC | 1.09 Billion USD | 55.461% |
| Evoke Pharma, Inc. | 5.18 Million USD | -9296.849% |
| Flora Growth Corp. | 76.07 Million USD | -539.95% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -45126.1% |
| Evolus, Inc. | 202.08 Million USD | -140.897% |
| HUTCHMED (China) Limited | 837.99 Million USD | 41.907% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 24.454% |
| Akanda Corp. | 2.16 Million USD | -22437.235% |